文献速递免疫规划妇幼与学校卫生

含遗传脱毒百日咳毒素的无细胞百日咳疫苗在感染与未感染HIV孕妇及其新生儿中的安全性与免疫原性(WoMANPOWER):乌干达一项随机对照试验

Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda.
PubMed 文献 · Lancet Glob Health · 2025-01-01

在乌干达开展观察者盲法、随机、2期、多中心非劣效试验,孕妇按HIV状态分层随机接受Td或含遗传脱毒百日咳毒素的TdaP疫苗。TdaP在HIV感染孕妇及其婴儿中安全且具免疫原性,分娩时抗百日咳毒素IgG浓度优于Td;但婴儿18周时接受全程细胞百日咳疫苗后,TdaP组婴儿抗百日咳毒素IgG浓度显著低于Td组,其临床意义因缺乏保护性相关指标而不明确。

要点

  • TdaP疫苗在HIV感染孕妇及其婴儿中安全,32例严重不良事件均与疫苗无关。
  • 分娩时婴儿抗百日咳毒素IgG浓度TdaP组优于Td组,HIV暴露未感染和未暴露婴儿均如此。
  • 18周时完成细胞百日咳疫苗后,TdaP组婴儿抗百日咳毒素IgG浓度显著低于Td组。

核心结论

  • TdaP在HIV感染孕妇及其婴儿中安全且具免疫原性,分娩时抗百日咳毒素IgG浓度优于Td。
  • 婴儿常规接种细胞百日咳疫苗后,TdaP组婴儿抗百日咳毒素IgG浓度低于Td组,因缺乏保护性相关指标,该发现的临床意义不明确。

研究设计与样本

  • 观察者盲法、随机、2期、多中心、非劣效试验,在乌干达评估含遗传脱毒无细胞百日咳疫苗在HIV感染孕妇中的安全性和免疫原性。
  • 孕妇年龄至少18岁、孕16至26周,随机接受Td或TdaP疫苗,按HIV状态分层区组随机(区组大小4,比例1:1:1:1),每组50人共200人。
  • 干预为0.5 mL单剂肌内注射TdaP疫苗,Td或TdaP按随机软件分配至不同门诊日。
  • 主要免疫原性终点为婴儿分娩时及接种三剂细胞百日咳疫苗后18周时的抗百日咳毒素和抗丝状血凝素IgG浓度。
  • 试验注册于ClinicalTrials.gov,NCT04589312。

主要发现

  • 2020年10月28日至2021年5月21日筛查438名孕妇,随机181名:TdaP组90名(HIV阳性40名、HIV阴性50名),Td组91名(HIV阳性41名、HIV阴性50名)。
  • 全部参与者接种Td,4周后177名接种Td或TdaP。
  • 发生32例严重不良事件,均与研究疫苗无关。
  • 分娩时抗百日咳毒素IgG浓度TdaP组 vs Td组:HIV暴露未感染婴儿几何均值比9.61(95%CI 5.21-17.74),HIV未暴露婴儿21.6(95%CI 11.2-41.7)。
  • 18周时抗百日咳毒素IgG浓度TdaP组母亲所生婴儿 vs Td组母亲所生婴儿:HIV暴露未感染婴儿0.19(95%CI 0.09-0.43),HIV未暴露婴儿0.17(95%CI 0.08-0.33),均显著降低。

局限性

  • 原文指出,因缺乏对抗百日咳疾病的保护性相关指标,该发现的临床意义不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunisation in pregnancy against pertussis can reduce severe disease in infancy. There are few data on the safety and immunogenicity of vaccines given to pregnant women living with HIV and their infants. We aimed to describe the safety and immunogenicity of a tetanus-diphtheria-acellular pertussis (TdaP) vaccine containing genetically detoxified pertussis toxin given to pregnant women living with HIV and the effect of the vaccine on infant whole-cell pertussis vaccine responses. METHODS: We conducted an observer-blind, randomised, phase 2, multicentre, non-inferiority trial evaluating safety and immunogenicity of a vaccine containing genetically detoxified acellular pertussis in pregnant women living with HIV in Uganda. Women aged at least 18 years between 16 weeks and 26 weeks of gestation were randomly assigned to receive the tetanus-diphtheria (Td) vaccine or TdaP vaccine. Stratified block randomisation using blocks of four with a 1:1:1:1 ratio stratified by participant HIV status was used to distribute participants into equal groups (50 participants per group for a total of 200 participants). The intervention was a 0·5 mL single intramuscular dose of TdaP vaccine. Td or TdaP vaccination was randomly assigned to different clinic days using randomisation software. Primary immunogenicity endpoints were anti-pertussis toxin and anti-filamentous haemagglutinin IgG concentrations in infants at delivery and 18 weeks following three doses of a whole-cell pertussis containing vaccine. This study is registered at ClinicalTrials.gov, NCT04589312. FINDINGS: Between Oct 28, 2020, and May 21, 2021, 438 pregnant women were screened and 181 were randomly assigned: 90 to TdaP vaccine (40 HIV-positive participants and 50 HIV-negative participants) and 91 to Td vaccine (41 HIV-positive participants and 50 HIV-negative participants). All participants received Td, and 4 weeks later, 177 received either Td or TdaP. 32 serious adverse events occurred, none related to the study vaccine. At delivery, anti-pertussis toxin IgG concentrations for TdaP versus Td were superior in infants who were HIV-exposed but uninfected (geometric mean ratio 9·61, 95% CI 5·21-17·74) and HIV-unexposed infants (21·6, 11·2-41·7). In infants at 18 weeks, anti-pertussis toxin IgG concentrations for TdaP versus Td-vaccinated mothers were significantly lower for both infants who were HIV-exposed but uninfected (0·19, 0·09-0·43) and infants who were not HIV-exposed (0·17, 0·08-0·33). Serum bactericidal antibody generation following whole-cell pertussis vaccination in infants was not affected. INTERPRETATION: TdaP was safe and immunogenic in pregnant women living with HIV and their infants. TdaP provided superior anti-pertussis toxin IgG concentrations at delivery. Following routine vaccination with whole-cell pertussis vaccine, infants born to women receiving the TdaP vaccine had lower anti-pertussis toxin IgG concentrations than infants born to women receiving Td. In the absence of a correlate of protection against pertussis disease, the clinical significance of this finding is unclear. FUNDING: Medical Research Council Joint Clinical Trials, Canadian Institutes of Health Research, and British Columbia Children's Hospital Research Institute.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Nakabembe E, Greenland M, Amaral K, et al. Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda. Lancet Glob Health. 2025. PMID: 39706666. doi:10.1016/S2214-109X(24)00409-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。